Lisuride in de novo parkinsonian patients: a four-year follow-up.
Lisuride at a mean daily dose of 3.2 mg was given to 15 untreated idiopathic Parkinson's disease patients. There were 10 dropouts, due mainly to inefficacy in the first months of therapy. The parkinsonian pattern in the patients who remained in the study for the full 4 years showed distinct improvement, which was maintained for less than 2 years. The patients did not develop "on-off" phenomena or abnormal involuntary movements during follow-up.
Giovannini
P
P
Department of Neurology, Institute of Neurology, C. Besta, Milan, Italy.
Scigliano
G
G
Piccolo
I
I
Soliveri
P
P
Suchy
I
I
Caraceni
T
T
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008090:Lisuride / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
D004873:Ergolines; D008090:Lisuride